Form 4: Sarepta Therapeutics Director Hans Wigzell Reports Stock and Option Transactions

Director Hans Wigzell reports acquisition of restricted stock units and exercise of stock options in Sarepta Therapeutics.

Summary

• On March 1, 2024, Hans Wigzell, a director of Sarepta Therapeutics, acquired 1,846 shares of common stock through restricted stock units (RSUs) at a price of $0.
• These RSUs will vest in full on March 1, 2025.
• On the same day, Wigzell also exercised stock options to purchase 3,679 shares of common stock at an exercise price of $128.67.
• Following these transactions, Wigzell directly owns 22,840 shares of common stock and 3,679 derivative securities.

Sentiment

Score: 5

Explanation: Neutral sentiment as this is a standard regulatory filing detailing insider transactions. The transactions themselves don't necessarily indicate positive or negative sentiment about the company's future.

Positives

• The acquisition of restricted stock units could be seen as a positive sign, indicating the director's alignment with the company's long-term success.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities, allowing the public to monitor transactions by company executives and directors.

Stakeholder Impact

• Shareholders can use this information to understand the actions of company insiders.

Key Dates